Skip to content

To examining the effects of ingestion of 1,5-anhydrofructose on the human mind and body

To examining the effects of ingestion of 1,5-anhydrofructose on the human mind and body : Randomized, placebo-controlled,double-blind, parallel-group comparison study - 1,5-Anhydrofructose intake test : Randomized,placebo-controlled, double-blind,parallel-group comparison study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000055271
Enrollment
35
Registered
2025-02-24
Start date
2024-01-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult

Interventions

To intake 1,5-AF capsules 6 tablets/day for 4 weeks. To intake placebo capsules without 1,5-AF, 6 tablets/day for 4 weeks.

Sponsors

User Life Science Co., Ltd.
Lead Sponsor
Edihas Co., Ltd
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Persons who are 50 years old or older but under 80 years old (2) Persons who is generally judged as healthy (3) Persons who are aware of their stress (4) Persons who can give voluntary written consent to participate in the present trial

Exclusion criteria

Exclusion criteria: (1) persons who have any dietary supplements, quasi drugs or medicines which cause same or similar efficacy with the effect evaluated in this study (2) persons who have changed their habitats to take supplements within past 4 weeks. (3) Persons who work in night shift or in day and night shift (4) persons who have been treated their illness or prevention in a clinic at their informed consent (5) persons with their medical histories as follows: serious diseases of sugar metabolism, lipid metabolism, hepatic function, renal function, heart, circulatory, respiratory, endocrine system, immune system, or mental illness of the nervous system (6) persons with the medical histories of alcoholism or drug dependence (7) persons who might be developed allergic reaction to foods. (8) Persons who are pregnant, breast-feeding, or hope to be pregnant during the study period (9) persons who had always participated in or will participate in any other clinical trial (to use foods/medicine/quasi medicine/medical device) (10) persons who will not be judged suitable to the participants by the investigator

Design outcomes

Primary

MeasureTime frame
Question paper 1.Profile of Mood States 2nd Edition Short Form for Adults 2.The Pittsburgh Sleep Quality Index

Secondary

MeasureTime frame
Hematological examination

Countries

Japan

Contacts

Public ContactKeiko Ohnuki

User Life Science Co., Ltd. The research and development part

userlifescience@gmail.com0948-82-3123

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026